Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
In this study, patients with relapsed or refractory ovarian cancer will receive treatment
with pazopanib and liposomal doxorubicin (Doxil) until disease progression or unacceptable
toxicity occurs. The Phase I portion will define the dose limiting toxicity (DLT) of
pazopanib and liposomal doxorubicin when administered in combination. Once the maximum
tolerated dose has been identified in the Phase I portion, the Phase II portion will evaluate
efficacy and safety of this combination in the same patient population.